Is the Ecstasy-induced ipsilateral rotation in 6-hydroxydopamine unilaterally lesioned rats dopamine independent?
H B Lebsanft, Andreas Mayerhofer, Karl-A Kovar, Werner J Schmidt
Journal of Neural Transmission July 1, 2003 DOI: 10.1007/s00702-003-0823-y (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental animal study Peer reviewed |
|---|---|
| Population | Male Sprague Dawley rats with unilateral 6-hydroxydopamine lesions of the medial forebrain bundle |
| Interventions | MDMA MBDB MDE MDA Citalopram PCPA |
| Dose | 2.5, 5.0 and 10.0 mg/kg MDMA; 5.0 mg/kg MBDB, MDE, MDA |
| Topics | MDMA |
| Key findings | MDMA and its derivatives induce ipsilateral rotations in a rat model of Parkinson's disease, with MDA being the most effective, and the effect is not fully explained by serotonin release or dopaminergic activity. |
Abstract
3,4-Methylenedioxymethamphetamine (MDMA) has recently been hypothesized to be effective against the symptoms of Parkinson's disease. Therefore we tested the effects of MDMA-derivatives in the rotational behavioural model. Male Sprague Dawley rats were lesioned unilaterally with 6-hydroxydopamine at the medial forebrain bundle. MDMA was administered at doses of 2.5, 5.0 and 10.0 mg/kg, its derivatives N-Methyl-1-(1,3-benzodioxol-5-yl)-2-butananamine (MBDB), 3,4-Methylenedioxy-N-ethylamphetamine (MDE) and 3,4-Methylenedioxyamphetamine (MDA) at 5.0 mg/kg respectively. All substances induced ipsilateral rotations, MDA being the most effective. MDMA induced rotations were attenuated by the selective serotonin reuptake inhibitor Citalopram but were only slightly reduced by pre-treatment with the selective serotonin synthesis inhibitor PCPA (para-chlorophenylalanine). The effects of MDMA can therefore not fully be explained by serotonin release or by dopaminergic activity of the drugs.
Comparable studies
Other preclinical and animal studies on MDMA, most cited first.
Citations in the library
Cites 19
- Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin Synapse 2000
- Differences Between the Mechanism of Action of MDMA, MBDB, and the Classic Hallucinogens. Identification of a New Therapeutic Class: Entactogens Journal of Psychoactive Drugs October 1, 1986
- Carrier‐Mediated Release of Serotonin by 3,4‐Methylenedioxymethamphetamine: Implications for Serotonin‐Dopamine Interactions Journal of Neurochemistry 1996
- The pharmacology of the acute hyperthermic response that follows administration of 3,4‐methylenedioxymethamphetamine (MDMA, ‘ecstasy’) to rats British Journal of Pharmacology 2002
- Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class Journal of Medicinal Chemistry October 1, 1986
and 14 more in the library